Results 61 to 70 of about 32,756 (214)

SIMULATION OF BIOEQUIVALENCE STUDY ON THE BASE OF DISSOLUTION CURVES [PDF]

open access: yes, 2018
A computer method and software based on the in vitro dissolution ofdrug preparations has been elaborated for the estimation of bioequivalenceusing Microsoft Excel 2007, Visual Basic programming language.
Dinya, Elek   +3 more
core  

Monkeypox Virus: Epidemiology, Virology, Diagnosis, Vaccine, and Therapeutics

open access: yesMedComm, Volume 7, Issue 1, January 2026.
This review provides a comprehensive overview of the latest research advances in MPXV, with a focused analysis across five core dimensions: epidemiology, virology, diagnosis, vaccine, and therapeutics. The primary objective of this review is to advance the understanding of MPXV and facilitate the development of more effective diagnostic methods ...
Yunzheng Yan   +14 more
wiley   +1 more source

Impact of Obesity and MASH on Zonal Hepatocellular Statin Exposure: Pharmacodynamic Insights From a Permeability‐Limited Multicompartment Liver Model

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.
Obesity, MASH and Statins: Insights from a PBPK/PD Zonal Liver Model. ABSTRACT Statins are frequently prescribed for hyperlipidemia, a common comorbidity in patients with obesity and/or metabolic dysfunction‐associated steatohepatitis (MASH). However, limited knowledge exists on how MASH may alter statin disposition within hepatocytes where the statin ...
William A. Murphy   +5 more
wiley   +1 more source

Bioequivalence of Sandoz methylphenidate osmotic‐controlled release tablet with Concerta® (Janssen‐Cilag) [PDF]

open access: gold, 2015
Elisabeth Schapperer   +5 more
openalex   +1 more source

Physiologically‐Based Pharmacokinetic Modeling of the PARP Inhibitor Niraparib

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.
ABSTRACT A physiologically‐based pharmacokinetic (PBPK) model of niraparib and its primary metabolite using a relevant virtual cancer population is reported here. A series of in vitro experiments using liver S9, microsomes, and hepatocytes with various inhibitors and recombinant supersomes demonstrated that niraparib is specifically metabolized by ...
Gareth J. Lewis   +3 more
wiley   +1 more source

Managing Delayed or Missed Doses of Prolonged‐Release Tacrolimus in Transplant Recipients: Implications for Drug Exposure and Recovery Strategies

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 138, Issue 1, January 2026.
This simulation–based analysis quantified the impact of delayed and missed doses of prolonged–release tacrolimus in kidney and liver transplant recipients. A single missed dose reduced AUC24h by up to 50% and required 2–4 days to return to steady state.
S. Arraki Zava   +6 more
wiley   +1 more source

Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma

open access: yesBritish Journal of Haematology, Volume 208, Issue 1, Page 337-342, January 2026.
Standard pomalidomide dosing (4 mg/day for 21 of 28 days) achieved the most robust pharmacokinetic (PK) and pharmacodynamic (PD) effects. Daily dosing with pomalidomide 2 mg is a safe alternative for patients at risk of toxicity; alternate‐day dosing was less effective.
M. R. Seefat   +21 more
wiley   +1 more source

On equivalence and bioequivalence testing. [PDF]

open access: yes, 2017
Equivalence testing is the natural approach to many statistical problems. First, its main application, bioequivalence testing, is reviewed. The basic concepts of bioequivalence testing (2×2 crossover designs, TOST, interval inclusion principle, etc.) and
Carrasco Jordan, Josep Lluís   +3 more
core  

Home - About - Disclaimer - Privacy